The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000804381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
20/06/2026
Date registered
Help: Date registered
6/07/2026
Date last updated
Help: Date last updated
6/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
6/07/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Feasibility Study to Evaluate a Continuous Blood Glucose Monitor in Adults with Diabetes Mellitus -Australia
Scientific title
A Feasibility Study to Evaluate the Safety and Effectiveness
of a Continuous Blood Glucose Monitor In Adults with Diabetes Mellitus
Additional trial identifiers [1] 317584 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Diabetes Mellitus 342343 0
Condition category
Condition code
Metabolic and Endocrine 338477 338477 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This human clinical trial will assess the feasibility of the Continuous Blood Glucose Monitoring (CBGM) System’s safety during long-term use as evidence by the absence of procedure and/or device related serious adverse event(s). Qualified participants who have signed informed consent will have the device implanted for up to 1-year during an outpatient procedure. They will attend clinic visits at 7-Days, 14-Days (follow-up with the procedural specialist/Investigator), 1-month, 3-months, 6-months, 9-months, and 11-months post Continuous Blood Glucose Monitoring (CBGM) System insertion. Device removal will occur following completion of the 11-month in-clinic visit, with a follow-up / final visit to review the wound site and safely exit the Participant from the study.
During post implant visits, Participants will undergo safety evaluations and a 6-hour Frequent Sample Testing (FST) session, during which venous blood samples will be collected every 15 minutes via an indwelling IV catheter and analyzed using a Nova Primary blood glucose tabletop reference analyzer (25 µL whole blood per sample).
During the FST, controlled hyperglycemic and hypoglycemic challenges will be induced by adjusting the timing and/or dose of rapid-acting insulin, physical activity, and carbohydrate intake. These interventions will be individualized based on each participant’s usual insulin regimen and meal patterns and will be authorized and supervised by the endocrinology team's qualified clinical research staff.
Outside of the clinic, Participants will complete up to 3 fingerpricks per day (with a study provided commercially approved Blood Glucose (BG) meter), carry a study phone to collect investigational sensor data (data is blinded to Participant), complete a study diary (to collect any safety events or medications taken, etc. in between visits), and wear a study provided commercial Continuous Glucose Monitor (CGM) sensor per approved manufacturer’s instructions for use (with minimum wear to occur at least during the time of the in-clinic visits).
Removal of the investigational device will be similar to the insertion procedure. A final 14-day post removal visit will occur to follow-up with the participant to assess the sensor insertion site. If there are no outstanding adverse events or items for follow-up, this will be considered the participant’s final visit, and they can safely exit the study
.
Intervention code [1] 334390 0
Treatment: Devices
Description of the comparator or control
Nova Primary blood glucose reference analyzer
-Nova Primary training will occur during site initiation, and only trained clinic research staff will operate and maintain the device.
-the tabletop analyzer requires a 25 ul blood sample and approximately 2 minutes to run the test.
- 6-hour FSTs with 15-minute sampling conducted at specified Participant clinic visits as listed above.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345766 0
Absence of serious procedure and/or device related adverse events from sensor insertion through 14 days post explant assessed as a composite primary outcome.
Timepoint [1] 345766 0
continuous assessment evaluated at each clinic visit from baseline through 14-days post removal visit (final visit).
Secondary outcome [1] 463212 0
CBGM System performance
Timepoint [1] 463212 0
continuous assessment from device implant through device explant.
Secondary outcome [2] 463213 0
CBGM System Accuracy
Timepoint [2] 463213 0
In-clinic visits that include a 6-hour Frequent Sample Test (FST): 7-Days, 1-month, 3-month, 6-month, 9-month, and 11-months post insertion visits.

Eligibility
Key inclusion criteria
1. Age 21 to 75 years old inclusive.
2. Generally, in good health, as determined by the investigator.
3. Clinical diagnosis of type 1 or type 2 diabetes for at least 3 years
4. Insulin Therapy – 3 plus injections/day or Continuous Subcutaneous Insulin Infusion (CSII) in Participants with type 1 diabetes, or with basal insulin or multi-dose insulin regimen in Participants with type 2 diabetes.
5. HbA1c < 9.0 % as reported on baseline laboratory result.
6. BMI in the range 18–32 kg/m2.
Minimum age
21 Years
Maximum age
75 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Any biochemical profile, full blood examination or differential result that falls outside the laboratory’s reference range and deemed by the investigator as clinically significant or indicative of a serious chronic illness.
2. History of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or blood clotting disorder that, in the opinion of the Investigator, would compromise the safety of the study Participant.
3. Female Participant of childbearing potential who has a positive pregnancy screening test or who is planning to become pregnant or not using adequate method of contraception deemed reliable by Investigator.
4. One (1) or more episodes of hypoglycemia or diabetic ketoacidosis (DKA) in the last 6 months requiring an emergency room (ER) visit or hospital admission.
5. Known cardiovascular disease that, in the opinion of the Investigator, would compromise the safety of the study Participant.
6. End Stage Renal Disease on hemodialysis.
7. Current participation in another clinical drug or device study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety
Statistical methods / analysis
Data obtained from a limited sample size, therefore no formal statistical considerations.

Recruitment
Recruitment status
Stopped early
Data analysis
No data analysis planned
Reason for early stopping/withdrawal
Other reasons/comments
Other reasons
Planned investigational device iteration.
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 322143 0
Commercial sector/Industry
Name [1] 322143 0
Glucotrack Australia PTY LTD.
Country [1] 322143 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Glucotrack Australia PTY LTD.
Address
Country
Australia
Secondary sponsor category [1] 325034 0
None
Name [1] 325034 0
Address [1] 325034 0
Country [1] 325034 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320674 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 320674 0
Ethics committee country [1] 320674 0
Australia
Date submitted for ethics approval [1] 320674 0
06/12/2024
Approval date [1] 320674 0
16/04/2025
Ethics approval number [1] 320674 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151242 0
Dr David O'Neal
Address 151242 0
St Vincent's Hospital, 35 Victoria PArade Fitzroy 3065 VIC
Country 151242 0
Australia
Phone 151242 0
+61 392882012
Fax 151242 0
Email 151242 0
Contact person for public queries
Name 151243 0
Paul Goode
Address 151243 0
Glucotrack, Inc. 301 Route 17 North Suite 800, Rutherford NJ 07070
Country 151243 0
United States of America
Phone 151243 0
+12018427715
Fax 151243 0
Email 151243 0
Contact person for scientific queries
Name 151244 0
Mark Tapsak
Address 151244 0
Glucotrack, Inc. 301 Route 17 North Suite 800, Rutherford NJ 07070
Country 151244 0
United States of America
Phone 151244 0
+12018427715
Fax 151244 0
Email 151244 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Data is blinded



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.